The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.
Ashley Yocum, PhD
Advertisement
Ashley Yocum, PhD, is the executive research strategy lead of the Beat AML Master Trial at the Leukemia & Lymphoma Society.
Articles by Ashley Yocum, PhD
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
At the European Hematology Association (EHA) 2025 Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
3
New Biomarkers, Drug Targets Identified for Colorectal Cancer
4
Colorblind Devices, Longer-Wavelength Lasers Offer Safer Options for Darker Skin Tones: Ariella Kauvar, MD
5
